Profile data is unavailable for this security.
About the company
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger RNA (mRNA). The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. The Company develops technologies that enable the development of mRNA medicines for diverse applications. The Company has created modalities, including Prophylactic vaccines, Systemic secreted and cell surface therapeutics, Cancer vaccines, Intratumoral immuno-oncology, Localized regenerative therapeutics, and Systemic intracellular therapeutics. Its diverse development pipeline which consists of 27 development candidates across its 24 programs.
- Revenue in USD (TTM)7.02bn
- Net income in USD3.49bn
- Incorporated2016
- Employees1.30k
- LocationModerna Inc200 Technology SqCambridge 02139-3578United StatesUSA
- Phone+1 (617) 714-6500
- Fax+1 (617) 583-1998
- Websitehttps://www.modernatx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 26.64bn | 5.16bn | 84.80bn | 13.60k | 16.60 | 4.30 | 12.06 | 3.18 | 4.07 | 4.07 | 21.04 | 15.71 | 0.4299 | 3.75 | 7.26 | 1,958,677.00 | 8.29 | 11.05 | 9.97 | 13.30 | 80.14 | 81.92 | 19.28 | 27.47 | 1.19 | 3.10 | 0.6049 | 43.07 | 9.98 | -5.43 | -97.72 | -63.15 | -2.74 | 16.09 |
| Zoetis Inc | 7.41bn | 1.91bn | 95.84bn | 11.30k | 50.63 | 22.04 | 40.73 | 12.93 | 3.99 | 3.99 | 15.50 | 9.17 | 0.5463 | 1.33 | 6.88 | 655,929.20 | 14.05 | 12.99 | 16.41 | 15.24 | 69.67 | 67.87 | 25.72 | 22.13 | 2.51 | 10.71 | 0.6231 | 21.88 | 6.63 | 6.97 | 9.20 | 37.03 | 15.13 | 19.23 |
| Amgen, Inc. | 25.48bn | 5.75bn | 118.02bn | 24.30k | 21.13 | 14.36 | 12.81 | 4.63 | 9.84 | 9.84 | 43.75 | 14.48 | 0.4085 | 1.58 | 5.18 | 1,048,724.00 | 9.21 | 11.20 | 11.53 | 13.36 | 75.34 | 80.70 | 22.55 | 33.20 | 1.03 | 9.70 | 0.799 | 44.50 | 8.83 | 3.25 | -7.37 | 0.9197 | 0.467 | 15.16 |
| Bristol-Myers Squibb Co | 44.38bn | -5.08bn | 129.68bn | 30.25k | -- | 3.52 | 22.71 | 2.92 | -2.27 | -2.27 | 19.60 | 16.57 | 0.3716 | 4.32 | 6.16 | 1,467,240.00 | -4.24 | 2.55 | -5.15 | 3.19 | 78.02 | 72.44 | -11.40 | 5.97 | 1.42 | -- | 0.5505 | 192.95 | 62.62 | 20.75 | -362.14 | -- | -1.69 | 3.99 |
| Moderna Inc | 7.02bn | 3.49bn | 130.87bn | 1.30k | 40.47 | 19.49 | 36.40 | 18.64 | 8.01 | 8.01 | 16.99 | 16.64 | 0.7149 | -- | 6.84 | 5,399,735.00 | 35.59 | -- | 65.71 | -- | 84.20 | -- | 49.79 | -- | 1.17 | -- | 0.0677 | -- | 1,234.34 | -- | -45.34 | -- | -- | -- |
| AbbVie Inc | 53.73bn | 6.60bn | 193.21bn | 48.00k | 29.43 | 15.37 | 12.51 | 3.60 | 3.72 | 3.72 | 30.24 | 7.11 | 0.3612 | 4.95 | 5.88 | 1,143,170.00 | 4.49 | 7.73 | 5.47 | 9.72 | 65.71 | 73.81 | 12.42 | 18.07 | 0.7884 | 6.49 | 0.8671 | 97.15 | 37.69 | 14.91 | -41.90 | -2.40 | 8.45 | 18.50 |
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 30 Jun 2021 | 45.88m | 11.37% |
| The Vanguard Group, Inc.as of 30 Jun 2021 | 19.45m | 4.82% |
| BlackRock Fund Advisorsas of 30 Jun 2021 | 14.29m | 3.54% |
| SSgA Funds Management, Inc.as of 30 Jun 2021 | 7.33m | 1.82% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2021 | 6.88m | 1.70% |
| Coatue Management LLCas of 30 Jun 2021 | 6.14m | 1.52% |
| Th�l�me Partners LLPas of 30 Jun 2021 | 6.07m | 1.50% |
| Morgan Stanley Investment Management, Inc.as of 30 Jun 2021 | 4.24m | 1.05% |
| Lone Pine Capital LLCas of 30 Jun 2021 | 3.99m | 0.99% |
| Geode Capital Management LLCas of 30 Jun 2021 | 3.36m | 0.83% |
